Guoxin Pharma (国信医药) is a clinical CRO founded in 2008 that provides comprehensive clinical research service solutions for pharmaceuticals and biological products. The company partners with more than 900 tertiary hospitals, over 600 clinical research institutions and 160+ pharmaceutical firms, and has completed over 380 clinical trials. It has been ranked among the national top-20 pharmaceutical R&D outsourcing providers for three consecutive years and is recognized as a national and Zhongguancun high‑tech enterprise. Financially, Guoxin recently completed a near-¥100M B round and had raised a near-¥100M A round in September 2020. Management says the new capital will be deployed to deepen innovative drug clinical research and post‑marketing studies and to expand gene and cell therapy services and clinical-trial medical testing.

Total raised

$16M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2021